Form 4: Bio-Rad Laboratories EVP Michael Crowley Reports Stock Transactions

Michael Crowley, EVP of Global Commercial Operations at Bio-Rad Laboratories, reports the exercise of stock options and subsequent sale of shares on March 14, 2025.

Summary

• On March 14, 2025, Michael Crowley, EVP of Global Commercial Operations at Bio-Rad Laboratories, exercised stock options to acquire 3,000 shares of Bio-Rad A Common Stock at a price of $159.32 per share.
• Following the exercise of the options, Crowley sold 3,000 shares at a weighted average price of $247.0614, with individual sales ranging from $245.0239 to $249.1550.
• After these transactions, Crowley directly owns 8,171 shares of Bio-Rad A Common Stock.
• The exercised options were part of a non-qualified stock option grant that became exercisable in five equal annual installments starting September 7, 2017.

Sentiment

Score: 5

Explanation: Neutral sentiment as it is a standard regulatory filing detailing stock transactions. The information itself doesn't inherently indicate positive or negative sentiment about the company's performance.

Positives

• The exercise of stock options and subsequent sale suggests confidence in the company's prospects, as the executive chose to exercise the options and then capitalize on the market price.

Negatives

• The sale of shares by an executive could be interpreted negatively by some investors, although it is a common practice for executives to diversify their holdings.

Risks

• There are no specific risks mentioned in this document, but the sale of shares by an executive could create short-term price volatility.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when corporate insiders, like Michael Crowley, transact in their company's stock. It provides transparency to the market regarding insider activity.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their executives.
• The information disclosed is consistent with SEC regulations and reporting requirements.
• Similar filings can be observed for executives at comparable companies in the life sciences and diagnostics industries, such as Danaher, Thermo Fisher Scientific, and Agilent Technologies.

Stakeholder Impact

• Shareholders may be interested in the insider's transactions as an indicator of management's view of the company's prospects.

Key Dates